Hansoh’s overseas ambitions tested as EU stalls cancer drug sales
The Chinese firm has lost its regulatory approval to sell a lung cancer drug in Europe over a data-protection error, and must reset the clock on the launch process Key…
FAST NEWS: Antengene’s loss widens on lower forex income, rising R&D costs
The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) reported last Friday its net loss for the first half of 2023 widened 51.5% year-on-year to 144 million yuan ($19.8 million). Looking up: The…
FAST NEWS: Antengene appoints Hansoh to commercialize myeloma drug
The latest: Antengene Corporation Ltd. (6996.HK) announced Friday it has entered into an exclusive collaboration agreement with Hansoh Pharmaceutical Group Co. Ltd. (3692.HK) for the commercialization of the relapse or…
RELATED ARTICLES
-
Cancer drug sales power up Kelun-Biotech’s profit engine
6990.HK -
Drug setback leaves Ascletis with an all-in bet on weight loss
1672.HK
- Insilico revenue soars above $100 million on AI drug partnerships
-
TransThera completes late-stage trial enrollment for Tinengotinib cancer drug
2617.HK
-
Biokin’s world-first bispecific ADC hits milestones, speeding commercialization
688506.SHG
-
Salubris refiles for Hong Kong IPO as generics lose steam
002294.SHE
